コンテンツへスキップ
Merck
  • Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models.

Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models.

Acta pharmacologica Sinica (2011-11-08)
Zhi-fei Wang, Emily Bame Fessler, De-Maw Chuang
要旨

The mood stabilizers lithium, valproate and lamotrigine are traditionally used to treat bipolar disorder. However, accumulating evidence suggests that these drugs have broad neuroprotective properties and may therefore be promising therapeutic agents for the treatment of neurodegenerative diseases, including stroke. Lithium, valproate and lamotrigine exert protective effects in diverse experimental stroke models by acting on their respective primary targets, ie, glycogen synthase kinase-3, histone deacetylases and voltage-gated sodium channels, respectively. This article reviews the most recent findings regarding the underlying mechanisms of these phenomena, which will pave the way for clinical investigations that use mood stabilizers to treat stroke. We also propose several future research avenues that may extend our understanding of the benefits of lithium, valproate and lamotrigine in improving stroke outcomes.

材料
製品番号
ブランド
製品内容

Supelco
ラモトリジン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
ラモトリジン, ≥98%, powder
Supelco
ラモトリギン 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
ラモトリジン, United States Pharmacopeia (USP) Reference Standard
ラモトリジン, European Pharmacopoeia (EP) Reference Standard
システム適合性用ラモトリジン, European Pharmacopoeia (EP) Reference Standard
ラモトリジン, European Pharmacopoeia (EP) Reference Standard